JSPR Company Profile and Key Details

Jasper Therapeutics, Inc. generated EPS of -$5.90 over the past year. Five-year average earnings growth is 54.53%. Wall Street analysts project EPS growth of 27.4% annually over the next five years. The latest quarter delivered EPS of -$0.10. The next quarter is forecast at -$0.71. Next year's EPS is expected at $0.45. Analyst sentiment is neutral. Analyst rating data shows there are 3 Strong Buy ratings, 1 Buy ratings, 3 Hold ratings, 0 Sell rating and 0 Strong Sell ratings. Price targets range from $14.00 to $1.50. The high target offers 2021.21% upside. The low target suggests 127.27% downside. The mean target is $6.07. This offers 819.7% upside. Jasper Therapeutics, Inc. earnings surprise history is a mixed track record. The quarter that ended August 14, 2026, missed forecasts by -62.66%. The prior quarter beat by -62.66%. Over the last six quarters, Apple has recorded several small beats. These include 45.0% in August 13, 2025.

Jasper Therapeutics, Inc. (NASDAQ:JSPR) closed at $0.66 USD, losing -$0.04 (-5.77%) from the previous close of $0.70. The stock is currently mid-range between its 52-week high and low $0.32 and $2.69. With a market capitalization of about $10.73 million, Jasper Therapeutics, Inc. is classified as a micro-cap and shows higher-than-market volatility (beta ~3.04). Key stats such as the average daily volume over the past year has been around 1.44 million shares, volume is running light vs its 52-week average. Headquartered in Redwood City, CA, Jasper Therapeutics, Inc. operates in the Healthcare sector and the Biotechnology industry. Led by CEO Jeetinder Singh Mahal, the company employs approximately 22 people and listed since January 10, 2020. Jasper Therapeutics, Inc., a clinical-stage biotechnology company, focuses on developing therapeutics targeting mast and hematopoietic stem cell driven diseases.

Jasper Therapeutics, Inc. last paid a dividend of 0 per share, Dividend and splits history remains an important factor for investors monitoring long-term returns. A discounted cash flow model estimates fair value at around $1.43. This means the shares are trading below this model’s fair value.

JSPR has shown mixed momentum, gaining 4.05% over the past week and -37.14% over the past quarter, though year-to-date performance is down -15.85%. Short-term trend indicators are bullishly aligned (SMA20 1.67%, SMA50 -12.06%, SMA200 -51.13%). The stock’s 14-day RSI is 47.05 (neutral), while the ATR of 0.11 points to higher daily volatility. The stock remains hovering near 52-week lows, trading -80.95% below its high and over 23.42% above its low. Average 10-day trading volume of 346.81 thousand shares is below the 3-month average of 1.11 million, indicating normal recent market interest.

Jasper Therapeutics, Inc. has 33.27 million shares outstanding. The public float is 30.01 million shares, elevated short interest at 13.20% of float. This equals 4.31 million shares. The short ratio is 1.53 days. Institutional investors hold 48.87% of the float. Insiders own 2.56%. Qiming U.S. Healthcare Fund II, L.P. holds 8.52 million shares, ROCHE HOLDING LTD has 4.55 million shares and Velan Capital Investment Management LP has 1.19 million shares. Over the past six months, insider transactions show net buying. They sold 0.00 shares across 0 transactions.

Jasper Therapeutics, Inc. trades at a P/E ratio of -0.43, slightly below the S&P 500 average, with a price-to-sales ratio of 0.0 and a price-to-book ratio of 13.82 reflecting a rich premium to book value. The P/FCF stands at -0.18, also above market averages. Compared to sector medians, Jasper Therapeutics, Inc. P/S is trading at a discount to the sector, and the P/B is far lower than peers, underscoring the brand and earnings power premium investors assign to the stock.

Our AI price prediction model suggests that Jasper Therapeutics, Inc. stock has strong potential for upside but may face short-term weakness followed by gains in the medium and long term. 2-Week Outlook: Projected increase of 9.04%, with price expected at $0.72 by September 24, 2026, within a range of $0.63 to $0.80 3-Month Outlook: Projected rise of 231.67%, reaching $2.19 by December 09, 2026, with a range of $1.77 to $2.32. 1-Year Outlook: Projected loss of -100.0%, with price at $0.00 by September 10, 2027, within a range of $0.00 to $1.33.

Jasper Therapeutics, Inc. (NASDAQ:JSPR) shares are down -15.85% year-to-date currently trading near 52-week highs band. Short-term momentum has been negative over the last quarter, despite recent volatility. Valuation shows Jasper Therapeutics, Inc. trading at a premium to the broader market with a P/E of -0.43. Analyst sentiment is cautious, with the majority of ratings in Sector Perform territory and a mean price target of $30.65, suggesting 4541.83% upside. Our AI forecast model points to short-term strength (9.04% over two weeks), a medium-term rise (231.67% over three months), and a longer-term loss (-100.0% over one year), with expected trading ranges indicating moderate volatility.